如何選擇EGFR突變肺癌的標靶藥物？ How to Choose Targeted Therapy for EGFR-Mutated Lung Cancer?

中文說明： 隨著健保第三代標靶藥物的全面給付，EGFR突變肺癌的治療選擇變得更多元。這段影片將分享臨床醫師在選擇第二代與第三代標靶藥物時的考量，包括腦轉移、基因變異類型等因素，並討論第三代藥物的優勢與限制。透過這次解說，幫助病患及家屬理解選擇藥物背後的臨床邏輯，以做出更適合的治療決策。

With Taiwan’s health insurance now covering third-generation targeted therapy, treatment options for EGFR-mutated lung cancer have expanded. This video will explore the clinical considerations between second- and third-generation drugs, including factors like brain metastasis and specific gene mutations, as well as the advantages and limitations of third-generation therapies. This insight aims to help patients and families understand the clinical decision-making process behind choosing the most suitable treatment.